MIRA Pharmaceuticals, Inc. Capitalization, Long-term Debt and Equity
MIRA Pharmaceuticals, Inc. (MIRA) had Capitalization, Long-term Debt and Equity of $50.00 million as of 2025-12-16, per its 10-K filed 2026-03-31.
Financial Statements › Notes
us-gaap:CapitalizationLongtermDebtAndEquity · last filed 2026-03-31
- 2025-12-16: Capitalization, Long-term Debt and Equity $50.00M.
- 2025-07-18: Capitalization, Long-term Debt and Equity $25.00M.
| Period end | Capitalization, Long-term Debt and Equity |
|---|---|
| 2025-12-16 | $50.00M 10-K · filed 2026-03-31 |
| 2025-07-18 | $25.00M 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |